The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer.
 
Tsuyoshi Konishi
No Relationships to Disclose
 
Eiji Shinozaki
No Relationships to Disclose
 
Keiko Murofushi
No Relationships to Disclose
 
Masashi Ueno
No Relationships to Disclose
 
Yosuke Fukunaga
No Relationships to Disclose
 
Satoshi Nagayama
No Relationships to Disclose
 
Yoshiya Fujimoto
No Relationships to Disclose
 
Takashi Akiyoshi
No Relationships to Disclose
 
Mitsukuni Suenaga
No Relationships to Disclose
 
Satoshi Matsusaka
No Relationships to Disclose
 
Akiko Chino
No Relationships to Disclose
 
Hiroshi Kawachi
No Relationships to Disclose
 
Noriko Yamamoto
No Relationships to Disclose
 
Yuichi Ishikawa
Honoraria - Chugai Pharma; Leica Biosystems; Lilly; Otsuka; Pfizer; Sysmex
Consulting or Advisory Role - Fujirebio Diagnostics
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Sony (Inst)
 
Masahiro Igarashi
No Relationships to Disclose
 
Masahiko Oguchi
No Relationships to Disclose
 
Nobuyuki Mizunuma
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Takeshi Sano
No Relationships to Disclose
 
Toshiharu Yamaguchi
No Relationships to Disclose